ABVX.PA ABIVAX | FR0012333284
Company Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Latest News
Alphabet's Waymo Hit With Dozens of Parking Tickets
GuruFocus.com • 07/27/2026
Michael Burry Expands Bets Against Major Chip Stocks
GuruFocus.com • 07/27/2026
Microsoft Q4 Earnings Preview: What To Expect From Upcoming Report
GuruFocus.com • 07/27/2026
Apple Makes Privacy Central to Smart Glasses Push
GuruFocus.com • 07/27/2026
BMO Capital Adjusts Price Target on Healthpeak Properties to $25 From $24, Maintains Outperform Rating
MT Newswires • 07/27/2026
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.abivax.com |
| Audit Risk | 9 |
| Board Risk | 10 |
| Overall Risk | 10 |
| Market Cap | 9.73B |
| Forward P/E | -42.22 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -4.61 |
| Forward EPS | -2.64 |
| Book Value | 5.42 |
| Price-to-Book | 20.6 |
| Enterprise-to-Revenue | 1,724.94 |
| Enterprise-to-EBITDA | -33.41 |
| Earnings Date | 09/21/2026 |
| Earnings Call Date | |
| Revenue Average | 819,070 |
| Revenue Low | 0 |
| Revenue High | 1.63M |